Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery

Overview

Journal Curr Oncol

Publisher MDPI

Date 2025 Jan 24

PMID 39851932

Authors

Luke R Jackson

Anna Erickson

Kevin Camphausen

Andra V Krauze

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is a primary central nervous system malignancy with a median survival of 15-20 months. The presence of both intra- and intertumoral heterogeneity limits understanding of biological mechanisms leading to tumor resistance, including immune escape. An attractive field of research to examine treatment resistance are immune signatures composed of cluster of differentiation (CD) markers and cytokines. CD markers are surface markers expressed on various cells throughout the body, often associated with immune cells. Cytokines are the effector molecules of the immune system. Together, CD markers and cytokines can serve as useful biomarkers to reflect immune status in patients with GBM. However, there are gaps in the understanding of the intricate interactions between GBM and the peripheral immune system and how these interactions change with standard and immune-modulating treatments. The key to understanding the true nature of these interactions is through multi-omic analysis of tumor progression and treatment response. This review aims to identify potential non-invasive blood-based biomarkers that can contribute to an immune signature through multi-omic approaches, leading to a better understanding of immune involvement in GBM.

References

Marcus A, Gowen B, Thompson T, Iannello A, Ardolino M, Deng W . Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 2014; 122:91-128. PMC: 4228931. DOI: 10.1016/B978-0-12-800267-4.00003-1. View

Azam Z, To S, Tannous B . Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance. Adv Sci (Weinh). 2020; 7(22):2002015. PMC: 7675056. DOI: 10.1002/advs.202002015. View

Serot J, Bene M, Foliguet B, Faure G . Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium. J Neuroimmunol. 2000; 105(2):115-9. DOI: 10.1016/s0165-5728(99)00240-4. View

Chen H, Lin L, Wang M, Lee S, Tsai M, Tsai C . Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma. Oncotarget. 2016; 7(27):42485-42501. PMC: 5173150. DOI: 10.18632/oncotarget.9890. View

Kahn J, Hayman T, Jamal M, Rath B, Kramp T, Camphausen K . The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol. 2013; 16(1):29-37. PMC: 3870843. DOI: 10.1093/neuonc/not139. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Robilliard L, Yu J, Anchan A, Finlay G, Angel C, Graham E . Comprehensive Assessment of Secreted Immuno-Modulatory Cytokines by Serum-Differentiated and Stem-like Glioblastoma Cells Reveals Distinct Differences between Glioblastoma Phenotypes. Int J Mol Sci. 2022; 23(22). PMC: 9692434. DOI: 10.3390/ijms232214164. View

Conarroe C, Bullock T . Ready for Prime Time? Dendritic Cells in High-Grade Gliomas. Cancers (Basel). 2023; 15(11). PMC: 10251930. DOI: 10.3390/cancers15112902. View

Garcia C, Myint Z, Jayswal R, Wang C, Morgan R, Butts A . Hematological adverse events in the management of glioblastoma. J Neurooncol. 2021; 156(1):153-161. PMC: 8829911. DOI: 10.1007/s11060-021-03891-8. View

10.

Kierdorf K, Prinz M . Microglia in steady state. J Clin Invest. 2017; 127(9):3201-3209. PMC: 5669563. DOI: 10.1172/JCI90602. View

11.

Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H . Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α. Nat Commun. 2018; 9(1):559. PMC: 5805734. DOI: 10.1038/s41467-018-03050-0. View

12.

Le Rhun E, Oppong F, Vanlancker M, Stupp R, Nabors B, Chinot O . Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. Neuro Oncol. 2022; 24(9):1533-1545. PMC: 9435483. DOI: 10.1093/neuonc/noac070. View

13.

Mundt S, Greter M, Flugel A, Becher B . The CNS Immune Landscape from the Viewpoint of a T Cell. Trends Neurosci. 2019; 42(10):667-679. DOI: 10.1016/j.tins.2019.07.008. View

14.

Ahn S, Park J, Jang J, Ahn K, Hong Y, Yang S . The association between total lymphocyte count after concomitant chemoradiation and overall survival in patients with newly diagnosed glioblastoma. J Clin Neurosci. 2019; 71:21-25. DOI: 10.1016/j.jocn.2019.11.017. View

15.

Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S . Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. Am J Respir Crit Care Med. 2018; 198(6):777-787. DOI: 10.1164/rccm.201708-1707OC. View

16.

Martinez-Lage M, Lynch T, Bi Y, Cocito C, Way G, Pal S . Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol Commun. 2019; 7(1):203. PMC: 6902522. DOI: 10.1186/s40478-019-0803-6. View

17.

Wurdinger T, Deumelandt K, van der Vliet H, Wesseling P, de Gruijl T . Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. Biochim Biophys Acta. 2014; 1846(2):560-75. DOI: 10.1016/j.bbcan.2014.10.003. View

18.

Yabo Y, Heiland D . Understanding glioblastoma at the single-cell level: Recent advances and future challenges. PLoS Biol. 2024; 22(5):e3002640. PMC: 11139343. DOI: 10.1371/journal.pbio.3002640. View

19.

Sengupta S, Thaci B, Crawford A, Sampath P . Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int. 2014; 2014:952128. PMC: 4163479. DOI: 10.1155/2014/952128. View

20.

DAgostino P, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K . Brain dendritic cells: biology and pathology. Acta Neuropathol. 2012; 124(5):599-614. PMC: 3700359. DOI: 10.1007/s00401-012-1018-0. View